Shearman & Sterling advised Boston Scientific Corporation (NYSE: BSX) in its definitive agreement to acquire Baylis Medical Company for a purchase price of $1.75 billion, subject to customary purchase price adjustments. The transaction is expected to close in the first quarter of 2022, subject to the satisfaction of customary closing conditions for similar transactions.

The acquisition will expand the Boston Scientific electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG® and VersaCross® Transseptal Platforms as well as a family of guidewires, sheaths and dilators used to support left heart access.

The Shearman & Sterling team below included associates Andrew Calamari (New York-Mergers & Acquisitions), Austin Grossfeld (New York-Intellectual Property Transactions) and Eugene Kim (Washington, DC-Tax).

The Team